Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Single-Center, Prospective Clinical Cohort Study on Perioperative Management, Exposure, Multiorgan Outcomes, and Functional Recovery in Liver Transplantation

12. november 2026 oppdatert av: Yi Duan, Beijing Tsinghua Chang Gung Hospital

The objective of this observational study (a single-center, prospective, consecutively enrolled clinical cohort) is to establish a cohort of adult liver transplant recipients to correlate, within the same population, the recipients' preoperative status with graft condition, perioperative medical and therapeutic exposures, and dynamic physiological changes, as well as multiorgan outcomes and functional recovery; to identify factors associated with organ injury and difficulties in recovery; and to provide a basis for subsequent clinical validation and intervention studies. The study population consists of adult recipients aged ≥18 years who are scheduled to undergo their first single-liver transplant at this center; continuous enrollment is planned for 5 years, with a target of 450 participants, each followed for 12 months. Recipients undergoing repeat liver transplantation or combined organ transplantation will be included only in a separate expanded registry and analysis.

The primary research questions it aims to address are:

What is the incidence rate and 95% confidence interval of the patient-level composite outcome-defined as all-cause mortality or at least one of the predefined major organ complications (early graft dysfunction/graft failure, new-onset or worsening moderate-to-severe acute kidney injury, new-onset delirium or confirmed acute neurological event, major cardiovascular event, or major pulmonary complication)-within 30 days after the start of the transplant procedure? After accounting for preoperative disease severity, organ function, and graft condition, how are perioperative clinical exposures and physiological changes-such as circulatory, respiratory, temperature, and EEG parameters-associated with multiorgan outcomes and functional recovery at 12 months? Can prespecified dynamic physiological data provide additional information regarding risk or recovery beyond routine clinical data?

This study has no control group; no treatment will be assigned; routine monitoring, testing, or rehabilitation arrangements will not be altered; and no additional blood draws or tissue samples will be collected. Participants will:

Undergo preoperative baseline data collection and assessments of cognition, frailty, functional status, and quality of recovery; some participants will complete the sleep and mood extension modules (PSQI, HADS).

During the perioperative period, participants will allow the research team to record clinically generated treatment exposures and multimodal monitoring data, including circulatory, respiratory, temperature, and EEG parameters.

Participants will complete relevant follow-up visits and functional assessments on postoperative days 7, 30, and 90, as well as at 6 and 12 months, including the QoR-15, DAH-30/90, and assessments of cognition, frailty, functional status, and quality of life.

Follow-up should preferably be conducted in conjunction with routine follow-up visits; when necessary, survival, hospitalization, and living conditions may be verified via approved telephone contact. Additional clinical testing using residual serum and tissue samples is optional; refusal to provide these samples will not affect enrollment in the study.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Antatt)

450

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 102218
        • Rekruttering
        • Beijing Tsinghua Changgung Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

This is a single-center study, and the study population is sourced from Beijing Tsinghua Changgung Hospital. Adult recipients (aged ≥18 years) scheduled to undergo primary single liver transplantation at this center are consecutively screened during waitlist registration, inpatient preoperative evaluation, or pre-transplant preparation. With an estimated 100 adult liver transplant surgeries performed annually at this center, approximately 450 recipients are planned to be enrolled consecutively over a 5-year period.

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Scheduled to undergo primary single liver transplantation at this center.
  3. The participant or legally authorized representative has completed the ethically approved informed consent process.

(Note: Patients undergoing emergency transplantation, preoperative hepatic encephalopathy, intensive care, mechanical ventilation, and renal replacement therapy are eligible. Donor type and disease severity will be retained as stratification information.)

Exclusion Criteria:

  1. Age < 18 years.
  2. History of previous liver transplantation.
  3. This surgery is a combined organ transplantation.
  4. Refusal to participate.
  5. Unable to complete valid authorization under the informed consent procedure approved for this study.

(Note: Patients undergoing re-transplantation and combined organ transplantation may enter a separate extended registry within the same ethical framework, but will not be mixed into the primary analysis cohort of primary single liver transplantation and its sample size denominator.)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of participants with all-cause mortality or at least one major organ complication within 30 days after the start of transplant surgery, assessed according to preset clinical criteria (e.g., Olthoff definition, KDIGO criteria).
Tidsramme: From the start of surgery to 30 days postoperatively.
From the start of surgery to 30 days postoperatively.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. oktober 2026

Primær fullføring (Antatt)

22. oktober 2031

Studiet fullført (Antatt)

22. oktober 2032

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere